Area Editoriale
In this paper Bogal et al analyze retrospectively a 3 years database from a tertiary academic medical center which underwent an eus guided liver biopsy or a standard liver biopsy throught percutaneous/intragiugular route. The primary outcome assessed was any adverse events. Secondary outcomes included technical success resulting in tissue acquisition and diag- nostic adequacy of the sample for histologic analysis. The most common indication for LB was abnormal liver function tests. For the primary outcome, the rate of adverse events was low with five reported (<1%). There were two in the EUS- LB group, two in the PC-LB group, and one in TJ-LB group, and this difference was not statistically significant (P= 0.585). The technical success rate was 100 % in each group. The rate of diagnostic adequacy was 100% in TJ-LB group and 99% in both EUS-LB and PC-LB groups. This difference was not statistically significant (P=1.000). The most com- mon histologic finding was non-specific changes (33.7%) followed by non-alcoholic steatohepatitis (15.60 %). In comparison with PC-LB and TJ-LB, EUS-LB has comparable safety profile, technical success rate, and diagnostic adequacy. EUS-LB should be considered as an option for random liver biopsy.